Nanoform Finland Oyj · OMXHEX:NANOFH
Nanoform Finland Oyj — Q2 2026 Earnings Presentation
32 slides from Nanoform Finland Oyj's earnings presentation, Aug 20, 2026
Slide 1: Nanoform – Q2 2026
Nanoform – Q2 2026 Conference call and webcast for investors and analysts August 20th, 2026
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “est
Slide 3: Key Business Highlights
Introduction Nanoform Breaker & Slide Option 2 Key Business Highlights CEO Edward Hæggström Nanoform.com | @nanoform 3
Slide 4: Introduction to Nanoform
Introduction to Nanoform NANOFORM NANOFORM MIDTERM REVENUES TO NANOFORM OFFERING CUSTOMERS TECHNOLOGIES BUSINESS TARGETS NANOFORM BREAK THE WALL 2030 Small molecules Service fees 3 nanoformed medicines Global pharma launched by 2030 Development and Biologics Small molecules commercial milestones Mid
Slide 5: Key business highlights
Key business highlights Positive feedback from scientific advice meeting in the UK => on track to submit our first market authorization I application for nanoenzalutamide before year end II Significantly improved cash flow => 2026 cash burn target below EUR 10m on track Fuelled by our recent exclusi
Slide 6: Financials and Guidance
Financials Nanoform Breaker Slide & Option 2 Guidance CFO Albert Hæggström Nanoform.com | @nanoform 6
Slide 7: Nr of projects signed – proportion of GMP increasing
Nr of projects signed – proportion of GMP increasing Nanoform.com | @nanoform 7 7
Slide 8: Continued growth in income. Gross Margin above 90%
Continued growth in income. Gross Margin above 90% Nanoform.com | @nanoform 8 8
Slide 9: Operating expenses down by 33% in 1H => significant improvement in EBITDA
Operating expenses down by 33% in 1H => significant improvement in EBITDA Nanoform.com | @nanoform 9 9
Slide 10: Continued improvement in cash flow. Cash burn target 2026 <EUR 10m on track
Continued improvement in cash flow. Cash burn target 2026 <EUR 10m on track At the end of 2Q26, Nanoform had EUR 19m in cash, down from EUR 20.5m at the end of 1Q26 Nanoform.com | @nanoform 10
Slide 11: Nanoform near-term business targets 2026
Nanoform near-term business targets 2026 I Cash burn below EUR 10m II First marketing authorization application for a nanoformed medicine submitted III Increased number of non-GMP and GMP projects signed in 2026 To sign development and license/commercial supply agreements on several IV product kerne
Slide 12: Nanoform midterm business targets 2030
Nanoform midterm business targets 2030 3 Income* nanoformed growth EBIT margin medicines > 50% CAGR > 30% by 2030 launched 2026-2030 by 2030 * Revenue + other operating income (milestones, fees, royalties, profit shares etc.) Nanoform.com | @nanoform 12
Slide 13: Commercial
Commercial Nanoform Breaker Slide Option 2 CCO Christian Jones & CDO Peter Hänninen Nanoform.com | @nanoform 13
Slide 14: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide
Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide The purpose of the meeting The purpose of the meeting was to receive advice on the applicability of the hybrid application pathway for a marketing authorization application for nanoenzalutamide in the UK with the exi
Slide 15: Commercial overview
Commercial overview Nanoenzalutamide progresses forward on multiple development and regulatory paths and I strategy receives green light from UK MHRA II Exclusivity agreement with US biopharmaceutical company signed III 6 new customer projects signed in Q2 2026 (3 non-GMP and 3 GMP) Momentum acceler
Slide 16: Nanoform Product Kernel overview
Nanoform Product Kernel overview* Nanoform at Nanoform Product Kernels Nanoform Pre-Clinical (non-GMP) Nanoform Clinical (GMP) Market Expected Nanoform Development Targeted Pre- Dosage form PoP* / Delivery route First cGMP Phase 1 / Pilot Pivotal - final - First Dossier Earliest possible Originator
Slide 17: Biologics update
Biologics update Future of Biologics delivery & formulation • Subcutaneous delivery will become the dominant standard (>50%) for new and marketed biologics • Suspension formulations enable high drug concentrations → lower injection volumes, making them a preferred choice • Particle properties are cr
Slide 18: Established exclusivity market for subQ, only a handful of technology providers
Established exclusivity market for subQ, dozens of large companies targeting 100s of receptors, only a handful of technology providers Alexion Daiichi Regenero Un Target Receptor Acumen Argenx Biogen BMS GSK Lilly JnJ Merck Merus Novartis Oruka Pfizer Roche Sandoz Skye Takeda ViiV Vertex
Slide 19: Q&A
Q&A www.nanoform.com 19 San Diego - Chicago - New York - Lisbon - London - Cambridge - Bordeaux - Cologne - Stockholm - Helsinki - Tokyo | @nanoform Nanoform.com
Slide 20: Appendix
Nanoform Breaker Slide Q & A2 Option APPENDIX www.nanoform.com San Diego - New York - Lisbon - Oxford – London - Cambridge - Bordeaux - Stockholm – Budapest - Helsinki 20 Nanoform.com | @nanoform
Slide 21: Nanoform signs first Biologics technology exclusivity agreement - May 12th, 2026
Nanoform signs first Biologics technology exclusivity agreement - May 12th, 2026 ▪ Exclusivity agreement for ultra-high concentration subcutaneous delivery ▪ With a U.S. Nasdaq listed biopharmaceutical company ▪ Partner pays Nanoform a non-refundable initial $1m fee to secure exclusivity for one cli
Slide 22: Nanoenzalutamide project continues with multitrack strategy
Nanoenzalutamide project continues with multitrack strategy Evaluating selected national submissions in European markets that may accept the ∙ current data package ∙ Advancing further formulation work to also meet the remaining Cmax requirement Assessing a non-generic pathway for the current product
Slide 23: Nanoform mid-term annual income potential by 2030
Nanoform mid-term annual income potential by 2030 Exclusivity fees & royalties & profit share: > EUR 50m Commercial milestones, small molecules: > EUR 25m Commercial GMP supply, small molecules: > EUR 10m Development milestones, Biologics: > EUR 10m Development milestones, small molecules: > EUR 10m
Slide 24: Small Molecules - Proprietary technology
Small Molecules - Proprietary technology Green technology Controlled Expansion of Supercritical Solutions - CESS® Contro lled ➢ Relatively simple process developed through combining deep knowledge in physics, chemistry, and pharma The CESS® technology platform was described in detail in the IPO pros
Slide 25: Large molecules - Proprietary technology
Large molecules - Proprietary technology Green technology Nanoforming process for biologics API = active pharmaceutical ingredient Nebulization = turns liquid into mist Ionization = particles electrically charged Nanoform.com | @nanoform 25
Slide 26: Nanoform technology is proven with in-vitro, in-vivo, and clinical study results
Nanoform technology is proven with in-vitro, in-vivo, and clinical study results and experience with 100 unique molecules Oncology: Biologics: Hydrogels: Replaced ASD formulations with nanocrystalline high drug load Demonstrated, in partnership Shown high drug load formulations for Enza/Apalutamide.
Slide 27: Nanoform technologies supercharges performance of a wide variety of molecules
Nanoform technologies supercharges performance of a wide variety of molecules, products and indications Higher Dose Load Improved Superior Alternative Enhancement for Superior for Oral drugs, mAbs Bioavailability to ASD Challenging Target Reformulations Peptides and Proteins Formulations Product Pro
Slide 28: Nanoform Product Kernels
Nanoform Product Kernels Nanoform internal Development partners Commercial partners Product Kernel work Originator Originator 1. Value proposition around a medicine or or candidate, called ‘Product Kernel’ Supergeneric / High value medicine Supergeneric / High value medicine company company 1. Upfro
Slide 29: Attractive revenue model with pharma and biotech customers
Attractive revenue model with pharma and biotech customers Proof of Concept / Phase Phase I – III clinical trials Drugs on the market Proof of Process Certification Non-GMP GMP GMP • Proof of concept study - assessment of • API for clinical trials are manufactured in • Drugs that have passed the tri
Slide 30: Management team: Multi-disciplinary with international merits
Management team: Multi-disciplinary with international merits CEO & Co-founder; Ph.D. (Applied physics), MBA CFO and member of the Board; B.Sc. (Economics) Edward Hæggström • Professor at the University of Helsinki, Head of Electronics Research Lab. Albert Hæggström • 20 years of finance and investi
Slide 31: Board of directors: Top executives from leading industry positions
Board of directors: Top executives from leading industry positions Miguel Calado Albert Hæggström Chairman of the Board CFO and Board Member • Previously CFO at international particle engineering CDMO • 20 years of finance and investing experience company Hovione Group • Prior roles include position
Slide 32: CEO Edward Hæggström edward.haeggstrom@nanoform.com +358 50 317 54 93 CFO Albert Hæggström albert.haeggstrom@nanoform…
CEO Edward Hæggström edward.haeggstrom@nanoform.com +358 50 317 54 93 CFO Albert Hæggström albert.haeggstrom@nanoform.com +358 40 161 4191 DIR Henri von Haartman hvh@nanoform.com +46 76866 50 11 Nanoform.com | @nanoform